These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16389169)

  • 1. Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying.
    Asakawa A; Ueno N; Katagi M; Ijuin Y; Morita Y; Mizuno S; Inui T; Sakamaki R; Shinfuku N; Uemoto M
    J Diabetes Complications; 2006; 20(1):56-8. PubMed ID: 16389169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals.
    Yoshida N; Omoya H; Kato S; Ito T
    Arzneimittelforschung; 1993 Oct; 43(10):1078-83. PubMed ID: 8267674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility.
    Okamura K; Sasaki N; Yamada M; Yamada H; Inokuma H
    Res Vet Sci; 2009 Apr; 86(2):302-8. PubMed ID: 18723200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography.
    Endo J; Nomura M; Morishita S; Uemura N; Inoue S; Kishi S; Kawaguchi R; Iga A; Ito S; Nakaya Y
    J Gastroenterol; 2002; 37(11):888-95. PubMed ID: 12483243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes.
    Ozaki K; Monnai M; Onoma M; Muramatsu H; Yogo K; Watanabe T; Oda Y; Katagiri K; Arakawa H; Itoh Z; Omura S; Takanashi H
    J Diabetes Complications; 2008; 22(5):339-47. PubMed ID: 18413164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mosapride citrate on patients after vagal nerve, lower esophageal sphincter, and pyloric sphincter-preserving nearly total gastrectomy reconstructed by jejunal J pouch interposition, and postoperative quality of life.
    Tomita R; Igarashi S; Fujisaki S; Kusafuka T
    Hepatogastroenterology; 2008; 55(82-83):760-5. PubMed ID: 18613449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prokinetic effect of mosapride citrate on horse gastric emptying rates.
    Okamura K; Sasaki N; Fukunaka M; Yamada H; Inokuma H
    J Vet Med Sci; 2008 Jun; 70(6):627-8. PubMed ID: 18628607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.
    Aoki K; Kamiyama H; Masuda K; Togashi Y; Terauchi Y
    Endocr J; 2013; 60(4):493-9. PubMed ID: 23257734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.
    Irwin N; McClean PL; Patterson S; Hunter K; Flatt PR
    Biol Chem; 2009 Jan; 390(1):75-80. PubMed ID: 18937625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2009 Jan; 602(2-3):448-54. PubMed ID: 19038243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.
    Green BD; Irwin N; Cassidy RS; Gault VA; Flatt PR
    Peptides; 2006 Sep; 27(9):2343-9. PubMed ID: 16730098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice.
    Asakawa A; Inui A; Ueno N; Makino S; Fujino MA; Kasuga M
    Gastroenterology; 1999 Jun; 116(6):1287-92. PubMed ID: 10348810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats.
    Uchida M; Yamato S; Shimizu K; Amano T; Ariga H
    J Pharmacol Sci; 2013; 121(4):282-7. PubMed ID: 23514789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of gastric acid on gastric emptying and gastric distension-induced pain response in rats--effects of famotidine and mosapride.
    Keto Y; Hirata T; Takemoto Y; Yamano M; Yokoyama T
    Neurogastroenterol Motil; 2012 Feb; 24(2):147-53, e88. PubMed ID: 22066725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy.
    Asakawa H; Hayashi I; Fukui T; Tokunaga K
    Diabetes Res Clin Pract; 2003 Sep; 61(3):175-82. PubMed ID: 12965107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents.
    Liu YL; Malik NM; Sanger GJ; Andrews PL
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):326-33. PubMed ID: 16435157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice.
    Dubuc PU; Peterson CM
    J Pharmacol Exp Ther; 1990 Dec; 255(3):976-9. PubMed ID: 2124625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serotonin 5- HT4 receptor agonist (mosapride citrate)].
    Odaka T; Suzuki T; Seza A; Yamaguchi T; Saisho H
    Nihon Rinsho; 2006 Aug; 64(8):1491-4. PubMed ID: 16898619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.